LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/AAHKS Announces Position on Opioid Use for Joint Pain
Large Joints and Extremities

AAHKS Announces Position on Opioid Use for Joint Pain

February 14, 2019 2 min read Premium comments

Advertisement

AAHKS Announces Position on Opioid Use for Joint Pain
Courtesy of AAHKS
#aahks#opioidSecondary#markspangehl

The American Association of Hip and Knee Surgery (AAHKS) has issued a new position statement titled, “Opioid Use for the Treatment of Osteoarthritis of the Hip and Knee.”

Mark Spangehl, M.D., associate professor of Orthopaedic Surgery at the Mayo Clinic College of Medicine and one of the surgeons who crafted the new statement, explained the process behind AAHKS’s position paper to OTW. “The process initially involved a literature review of pertinent articles to 1) determine the extent of the opioid crisis in the United states (i.e., various statistics on usage and mortality) 2) evaluate methods of management of chronic pain secondary to osteoarthritis [OA] of the hip and knee.”

“The initial draft was composed and then reviewed by members of the AAHKS board of directors and representatives of the Hip Society and Knee Society who added further comment and edits. Once all the edits and changes were incorporated, the final version was presented to the AAHKS Board of Directors for approval.”

Dr. Spangehl, who is also program director for the Mayo Orthopaedic Residency Program in Arizona, explained further, “The take home message is that opioids should not be used as a first line treatment for acute or chronic symptoms of hip and knee osteoarthritis. Patients on chronic opioids have poorer outcomes following hip and knee replacement surgery. There is strong (including level 1) evidence that opioids are not superior to non-opioid medication for long-term pain relief from osteoarthritis of the hip and knee.”

Asked about any nuances involved in such prescribing that perhaps all surgeons are not familiar with, Dr. Spangehl added, “It is important the surgeon understand that opioids do not provide superior long-term relief for hip and knee OA symptoms over non-opioid medications.”

“If opioids are prescribed, patients should be made aware of the potential side effects which include dependency, drowsiness, constipation, nausea, altered mental alertness and tolerance (the need for strong dosages to achieve the same pain-relieving effect).”

“Additionally, these patients should ideally be under the care of a pain management specialist. The lowest effective dose, for the shortest possible duration, should be the goal if opioids are prescribed. Furthermore surgeons should also educate patients that, while non-opioid treatment modalities (ice, non-steroidal anti-inflammatories, acetaminophen, ambulatory walking aids, weight loss (in overweight individuals), modest non-impact exercises (with or without the guidance of a physical therapist) are usually effective, osteoarthritis can be a painful condition, and complete resolution of symptoms with no pain whatsoever may be unrealistic in moderate or severe OA.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy